Kura Oncology
KURA
122 hedge funds and large institutions have $762M invested in Kura Oncology in 2019 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 6 closing their positions.
1,800% more call options, than puts
Call options by funds: $19K | Put options by funds: $1K
333% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 6
53% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 30
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
43% more capital invested
Capital invested by funds: $531M → $762M (+$231M)
17% more funds holding
Funds holding: 104 → 122 (+18)
3.79% more ownership
Funds ownership: 83.95% → 87.74% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.2M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$11.5M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
+$9.95M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.68M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$7.03M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.83M |
| 3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$4.15M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.27M |
KURA Hedge Fund Activity: Q2 2019 in Review
122 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2019, worth a combined $762M — up 43% from $531M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KURA positions and 6 closed out — a net gain of 20 holders — while 46 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $50.2M. The largest seller was Goldman Sachs, cutting an estimated $7.03M.
- 122 institutional investors held Kura Oncology (KURA) as of Q2 2019, up from 104 in Q1 2019.
- Funds reported $762M of Kura Oncology stock for Q2 2019, up 43% quarter-over-quarter.
- 26 funds opened new Kura Oncology positions in Q2 2019 and 6 closed out, a net change of +20 holders.
- The largest Kura Oncology buyer in Q2 2019 was Fidelity Investments, an estimated $50.2M added.
- The largest Kura Oncology seller in Q2 2019 was Goldman Sachs, an estimated $7.03M sold.
Based on aggregated 13F filings for Q2 2019.